[{"id":"42eaa2bb-da4a-4921-abda-242b6741daf6","acronym":"KL140-Ⅲ-02-CTP","url":"https://clinicaltrials.gov/study/NCT04835142","created_at":"2021-04-08T13:52:28.774Z","updated_at":"2025-02-25T16:16:06.277Z","phase":"Phase 3","brief_title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","source_id_and_acronym":"NCT04835142 - KL140-Ⅲ-02-CTP","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Datalai (cetuximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 688","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 03/22/2023","primary_completion_date":" 03/22/2023","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-08-05"},{"id":"6e0bcdc7-b7dc-409d-a37d-34492eccabd0","acronym":"NIRVANA","url":"https://clinicaltrials.gov/study/NCT02799901","created_at":"2021-01-18T13:44:11.253Z","updated_at":"2024-07-02T16:35:29.147Z","phase":"Phase 2","brief_title":"Nivolumab Plus Radiotherapy in Advanced Melanoma","source_id_and_acronym":"NCT02799901 - NIRVANA","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type • BRAF V600 wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 07/28/2021","primary_completion_date":" 07/28/2021","study_txt":" Completion: 07/28/2021","study_completion_date":" 07/28/2021","last_update_posted":"2023-11-15"},{"id":"beb060a4-1968-45b0-a8c3-a9127b485c2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04017897","created_at":"2021-01-18T19:43:54.398Z","updated_at":"2024-07-02T16:36:58.201Z","phase":"Phase 2","brief_title":"The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma","source_id_and_acronym":"NCT04017897","lead_sponsor":"Yonsei University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type • BRAF V600 wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 52","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-07-12"},{"id":"0bf022e3-2504-4bd9-ab06-f6c2ad181d2c","acronym":"KL140-III-01","url":"https://clinicaltrials.gov/study/NCT03426371","created_at":"2021-01-18T16:54:11.832Z","updated_at":"2025-02-25T16:15:44.799Z","phase":"Phase 3","brief_title":"Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial","source_id_and_acronym":"NCT03426371 - KL140-III-01","lead_sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type • RAS wild-type • BRAF V600 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • leucovorin calcium • Datalai (cetuximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 570","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2018-02-08"}]